Zevra Therapeutics (ZVRA) to Announce Earnings on Wednesday

Zevra Therapeutics (NASDAQ:ZVRA) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.08 per share and revenue of $33.8830 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. On average, analysts expect Zevra Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Zevra Therapeutics Trading Up 1.9%

ZVRA traded up $0.19 during mid-day trading on Tuesday, hitting $10.25. 433,404 shares of the stock were exchanged, compared to its average volume of 1,359,316. The company has a market cap of $605.98 million, a PE ratio of 5.16 and a beta of 0.91. The firm’s fifty day moving average is $12.31 and its two-hundred day moving average is $10.53. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $15.03.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZVRA. Cantor Fitzgerald increased their target price on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research note on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Finally, BTIG Research lowered their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Monday, July 27th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $26.86.

Institutional Trading of Zevra Therapeutics

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its position in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning purchased a new stake in shares of Zevra Therapeutics during the 2nd quarter worth approximately $92,000. Quarry LP purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter worth approximately $103,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Zevra Therapeutics in the 2nd quarter valued at $99,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.